drugset / Trial / NCT03335774

Evaluate Safety and Efficacy of 25 mg Hydrocortisone Acetate Suppositories in Treatment of Internal Hemorrhoids

NCT03335774

Phase 2 Completed 103 enrolled Nivagen Pharmaceuticals Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A randomized, double-blind, placebo-controlled, multicenter, parallel group study of the safety and efficacy of Hydrocortisone Acetate Suppositories, 25 mg compared to placebo suppositories in the treatment of symptomatic internal hemorrhoids.

Timeline

Start
2019-02-12
Primary completion
2021-03-05
Completion
2021-03-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Hydrocortisone Other / unclassified 25 mg Rectal

Indications